# Infection Control Market

> Infection Control Market Research Report: Size, Share, Trend Analysis By Product Type (Disinfectants, Infection Control Supplies, Sterilization Equipment, Personal Protective Equipment), By Applications (Hospitals, Pharmaceuticals, Research Laboratories, Food Industry), By End Use (Healthcare, Commercial, Residential), By Distribution Channel (Online, Offline, Direct Sales) and By Regional (North America, Europe, South America, Asia-Pacific, Middle-East and Africa) - Growth Outlook & Industry Forecast To 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 6.90%
- **2025:** USD 109.50 Billion
- **2035:** USD 213.38 Billion
- **Key Players:** Steris plc, Getinge AB, Ecolab Inc., Fortive Corporation (ASP), Diversey Holdings, Belimed AG, Reckitt Benckiser Group, Owens & Minor (Halyard)

**Report ID:** MRFR/HC/4445-HCR · **Pages:** 200 · **Author:** Rahul Gotadki & Kinjoll Dey · **Last Updated:** July 03, 2026

**URL:** https://www.marketresearchfuture.com/reports/infection-control-market-5901

---

## Market Summary

The Global Infection Control Market size was valued at USD 44.5 Billion in 2024, and the market is projected to grow from USD 46.99 Billion in 2025 to USD 81.05 Billion by 2035, registering a CAGR of 5% during the forecast period 2025–2035. North America led the market in 2024 with over 40% share, generating around USD 17.8 Billion in revenue.
 
Rising prevalence of healthcare-associated infections and increasing emphasis on hygiene standards are major drivers of the market. Expanding healthcare infrastructure, growing awareness of infection prevention, and adoption of advanced sterilization technologies continue to accelerate global demand for infection control solutions.
 
Centers for Disease Control and Prevention estimates 1 in 31 hospital patients has at least one healthcare-associated infection daily, while World Health Organization reports 7–10% of hospitalized patients globally acquire infections, reinforcing strong demand for infection prevention solutions.

## Market Drivers

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| CMS HAI reimbursement penalties | ~18% | North America | Short-term | [1] |
| EPA ethylene oxide emission regulations | ~15% | North America, Europe | Short-term | [3] |
| AI infection surveillance adoption | ~14% | Global | Medium-term | [7] |
| Single-use device mandates | ~13% | Europe, Asia-Pacific | Medium-term | [8] |
| Hospital construction cycle in China and India | ~12% | Asia-Pacific | Long-term | [4] |
| Contract sterilization outsourcing expansion | ~10% | Global | Medium-term | [9] |
| Antimicrobial resistance (AMR) national action plans | ~9% | Global | Long-term | [10] |

### CMS HAI Reimbursement Penalties

The CMS Hospital-Acquired Condition Reduction Program now penalizes roughly 750 U.S. hospitals annually, withholding 1–3% of Medicare reimbursements for facilities in the worst-performing quartile for central-line-associated bloodstream infections (CLABSIs) and catheter-associated urinary tract infections (CAUTIs) [[1]](https://cms.gov). This penalty structure has redirected an estimated USD 1.8 Billion in capital toward upgraded environmental cleaning systems and automated hand-hygiene compliance monitoring over the past three years, making it the single most powerful short-term driver of the Infection Control Market in North America.

### EPA Ethylene Oxide Emission Limits

Finalized in Q4 2024, the EPA's revised National Emission Standards for Hazardous Air Pollutants require commercial sterilization facilities to cut EtO emissions by up to 90% [[3]](https://epa.gov). Hospitals that previously relied on centralized EtO processing are investing in point-of-use hydrogen peroxide gas plasma and vaporized peracetic acid systems, generating a replacement cycle valued at over USD 2.5 Billion across North America and Western Europe through 2030.

### AI-Driven Infection Surveillance

Real-time predictive analytics platforms—integrating electronic health records, hand-hygiene sensor data, and environmental microbiology results—are enabling infection preventionists to detect outbreak clusters 48–72 hours earlier than manual chart reviews [[7]](https://journalofhospitalinfection.com). Health systems deploying these platforms report 15–22% reductions in HAI rates within the first 18 months, creating strong ROI narratives that drive procurement budget approvals for the broader Infection Control Market.

### Asia-Pacific Hospital Construction Cycle

China's "Healthy China 2030" initiative targets 8.0 hospital beds per 1,000 population by 2030, up from 6.7 in 2023 [[4]](https://nhc.gov.cn). India's Ayushman Bharat scheme has funded over 150,000 Health and Wellness Centers, each requiring baseline sterilization and disinfection infrastructure. Together, these programs anchor Asia-Pacific as the fastest-growing contributor to the Infection Control Market.

## Restraints

## Restraints Impact Analysis

Restraint estimates are directional and reflect the degree to which each factor dampens adoption velocity rather than directly subtracting from the stated CAGR.

| Restraint | ~% Negative Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| High capital cost of low-temperature sterilizers | ~–12% | Global | Short-term | [11] |
| Inconsistent reprocessing regulations across markets | ~–10% | Asia-Pacific, South America | Medium-term | [12] |
| Shortage of certified sterile processing technicians | ~–9% | North America, Europe | Medium-term | [13] |
| Environmental concerns over chemical disinfectant runoff | ~–7% | Europe | Long-term | [14] |
| Price sensitivity in public-sector procurement | ~–6% | Emerging markets | Long-term | [15] |

### Capital Cost Barriers for Low-Temperature Sterilizers

A single hydrogen peroxide gas plasma sterilizer carries a list price of USD 120,000–180,000, excluding consumable cassettes that can add USD 15–25 per cycle [[11]](https://ecri.org). Community hospitals operating on thin margins often defer purchases, extending the useful life of aging [steam autoclaves](https://www.marketresearchfuture.com/reports/steam-autoclave-market-6645) and slowing the pace at which the Infection Control Market transitions to advanced chemistries.

### Workforce Shortages in Sterile Processing

The U.S. Bureau of Labor Statistics estimates a 16 percent shortfall between the supply of and demand for Certified Registered Central Service Technicians until 2030 [[13]](https://bls.gov). Staff shortages lead to longer turnaround times for instruments, reduced throughput at contract sterilizing centers and limited operational capacity available to the Infection Control Market, even when capital budgets are authorized.

### Regulatory Fragmentation

The criteria for reprocessing of medical devices are different in the ASEAN countries, and some of the countries have no enforceable guidelines at all [[12]](https://ec.europa.eu). The lack of consistency prevents international suppliers from releasing advanced sterilizing platforms in smaller markets, thereby limiting growth in segments of the Infection Control Market with the largest unmet need.

## Opportunities

## Infection Control Market Opportunities

### Contract Sterilization-as-a-Service

Specialist operators are establishing recurring-revenue platforms that may amortize EPA-compliant infrastructure over dozens of hospital clients, akin to managed print services [[9]](https://steris.com). This methodology lowers the barrier of entry to small hospitals and produces sticky long-term contracts, expanding the addressable Infection Control Market beyond typical capital-equipment sales.

### AI-Powered Antibiogram Analytics

Real-time antibiograms derived from facility-level antibiotic resistance data pooled on cloud platforms represent a high-margin data monetization possibility. By incorporating these insights into current monitoring dashboards, vendors can charge premium subscription fees while helping hospitals cut broad-spectrum antibiotic use by an estimated 12–18% [[7]](https://journalofhospitalinfection.com).

### Emerging-Market Hospital Accreditation

Joint Commission International (JCI) accreditation is increasingly a competitive differentiator for private hospitals in the Middle East, Southeast Asia, and Latin America [[15]](https://jointcommissioninternational.org). Accreditation requires documented infection prevention programs, creating demand pull for turnkey bundles of environmental monitoring hardware, chemical disinfectants, and compliance software across the Infection Control Market.

### UV-C and Pulsed-Xenon Robotic Disinfection

Automated room-disinfection robots that deliver UV-C or pulsed-xenon light are reducing terminal-cleaning times by 30–40% in early adopter facilities [[16]](https://cambridge.org). As unit costs decline below USD 80,000 and clinical evidence strengthens, these systems present a compelling adjacent-category growth vector for the Infection Control Market.

### Sustainable Disinfection Chemistries

European biocide regulations under the EU Biocidal Products Regulation (BPR) are pushing formulators toward low-toxicity, biodegradable chemistries [[14]](https://echa.europa.eu). Companies that develop effective plant-derived or electrolyzed-water solutions stand to capture share in an environmentally conscious segment of the Infection Control Market.

## Future Outlook

## Infection Control Market Future Outlook

### Autonomous Sterilization and Robotic Disinfection

By 2030, autonomous UV-C disinfection robots are expected to be deployed in over 15,000 acute-care facilities worldwide, up from approximately 4,500 in 2025 [[16]](https://cambridge.org). These systems will integrate with building-management platforms to trigger automated terminal cleaning cycles between patient discharges, reducing reliance on manual labor and lowering HAI rates in the Infection Control Market by an estimated 20–30%.

### Platform Economics and Bundled Service Models

The shift from capital equipment sales to subscription-based sterilization and monitoring platforms mirrors the broader healthcare-as-a-service trend. Vendors offering bundled hardware, consumables, compliance reporting, and workforce training under multi-year managed-service agreements will capture a disproportionate share of the Infection Control Market, particularly among mid-sized hospital networks lacking in-house biomedical engineering depth [[9]](https://steris.com).

### AMR Surveillance and Data Integration

The WHO's Global Antimicrobial Resistance and Use Surveillance System (GLASS) aims to enroll 120 countries by 2030, up from 87 in 2024 [[10]](https://who.int). National AMR action plans increasingly mandate facility-level antibiogram reporting linked to infection control dashboards, creating a data backbone that transforms the Infection Control Market from a product-centric industry to an intelligence-driven ecosystem.

### ESG and Sustainability in Infection Prevention

Scope 3 emissions reporting requirements under the EU's Corporate Sustainability Reporting Directive (CSRD) will pressure hospital supply chains to quantify the environmental impact of disposable PPE, chemical disinfectants, and sterilization energy consumption [[14]](https://echa.europa.eu). Manufacturers that offer lifecycle-assessment-verified products and carbon-neutral sterilization services will gain a competitive edge as sustainability becomes a procurement criterion in the Infection Control Market.

## Segment Insights

## Infection Control Market Segmentation

### By Products & Services

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Sterilization Products and Services | 39.10% share (2025) | EtO replacement and low-temperature platform adoption |
| Cleaning and Disinfection Products | USD 33.85 Billion (2025) | Surface disinfection protocol standardization |
| Protective Barriers | 7.15% CAGR (2026–2035) | Single-use surgical gown and drape mandates |
| Others | USD 10.42 Billion (2025) | Environmental monitoring and hand hygiene systems |

Sterilization Products and Services anchor the Infection Control Market with the largest revenue share, reflecting the capital-intensive nature of hydrogen peroxide gas plasma sterilizers and vaporized peracetic acid systems that hospitals are deploying to replace EtO-dependent workflows [[3]](https://epa.gov). The installed base of low-temperature sterilizers in U.S. hospitals grew by an estimated 22% between 2022 and 2025, with replacement demand expected to sustain double-digit unit shipment growth through 2028.

Protective Barriers represent the fastest-growing product segment as surgical facilities worldwide shift toward single-use gowns, drapes, and face shields in response to updated WHO surgical-site infection prevention guidelines [[8]](https://who.int). Contract manufacturers in China and Southeast Asia are scaling capacity to meet demand, compressing unit prices while expanding addressable volumes across the Infection Control Market.

### By Service Delivery Mode

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| In-House Infection Control | 49.10% share (2025) | Established hospital sterile processing departments |
| Contract Infection Control | 7.10% CAGR (2026–2035) | Outsourcing to specialist operators for compliance |

In-House Infection Control programs remain the majority delivery model, particularly among large integrated delivery networks with dedicated central sterile supply departments. Contract Infection Control services are gaining share as smaller and mid-sized hospitals seek to offload regulatory compliance burden and capital expenditure onto specialized third-party operators who serve multiple clients from centralized processing hubs.

### By End User

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Hospitals and Clinics | 35.15% share (2025) | Surgical volume concentration, ICU bed density |
| Ambulatory Surgery Centers | 7.25% CAGR (2026–2035) | Outpatient migration, accreditation tightening |
| Others | USD 18.95 Billion (2025) | Long-term care, dental, pharmaceutical manufacturing |

Hospitals and Clinics dominate end-user spending in the Infection Control Market because they concentrate the highest-acuity procedures and the largest number of indwelling devices susceptible to HAIs. Ambulatory Surgery Centers are the fastest-growing end-user segment, fueled by the ongoing migration of orthopedic, ophthalmologic, and gastroenterological procedures to outpatient settings that now face accreditation-driven sterilization requirements equivalent to inpatient facilities [[15]](https://jointcommissioninternational.org).

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Key Metric | Primary Investment Themes |
| --- | --- | --- |
| North America | 36.20% share (2025) | HAI penalty programs, EtO replacement cycle |
| Europe | 27.50% share (2025) | EU MDR reprocessing standards, biocide regulation |
| Asia-Pacific | 7.35% CAGR (2026–2035) | Hospital construction, public-health modernization |
| South America | USD 6.79 Billion (2025) | JCI accreditation, private-hospital expansion |
| Middle East & Africa | USD 5.80 Billion (2025) | Medical tourism, sovereign health-fund investments |
| Total | USD 109.50 Billion (2025) | — |

The Infection Control Market displays a mature-dominant, emerging-growth dynamic. North America commands the largest revenue share, while Asia-Pacific contributes the largest incremental volume through 2035.

### North America

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| US | 78.60% of regional share | CMS penalty enforcement, EtO regulations |
| Canada | 12.80% of regional share | Provincial infection prevention mandates |
| Mexico | 8.60% of regional share | Private hospital accreditation growth |

The United States remains the anchor of the North American Infection Control Market, driven by CMS Hospital Value-Based Purchasing penalties and the EPA's EtO emission rule that affects over 80 commercial sterilization facilities nationwide [[1]](https://cms.gov)[[3]](https://epa.gov). Canada's provincial health authorities have introduced standardized infection prevention scorecards tied to hospital funding, while Mexico's growing private hospital sector is adopting JCI-aligned infection control protocols to attract medical tourists.

### Europe

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Germany | 6.95% CAGR | KRINKO guidelines, medical-device reprocessing leadership |
| UK | USD 5.12 Billion (2025) | NHS infection prevention surcharges |
| France | 6.80% CAGR | Haute Autorité de Santé sterilization audits |
| Italy | USD 3.48 Billion (2025) | Regional healthcare modernization funds |
| Spain | 6.70% CAGR | Public-private hospital partnership expansion |
| Nordic Countries | USD 2.15 Billion (2025) | High per-capita healthcare spending |
| Russia | 6.50% CAGR | Federal hospital equipment renewal program |
| Rest of Europe | USD 4.85 Billion (2025) | EU cohesion fund investments in healthcare |

Germany's Commission for Hospital Hygiene and Infection Prevention (KRINKO) guidelines set some of the world's strictest standards for instrument reprocessing, making the country a bellwether for advanced sterilization adoption across the Infection Control Market in Europe [[12]](https://ec.europa.eu). The UK's NHS has implemented infection prevention surcharges that penalize trusts reporting above-threshold Clostridioides difficile rates, mirroring the CMS penalty model.

### Asia-Pacific

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| China | 34.50% of regional share | Healthy China 2030 hospital bed expansion |
| India | 7.60% CAGR | Ayushman Bharat, private-hospital growth |
| Japan | USD 4.95 Billion (2025) | Aging population, advanced sterilization adoption |
| South Korea | 7.10% CAGR | KFDA device reprocessing standards |
| ASEAN | USD 3.28 Billion (2025) | Medical tourism, accreditation-driven demand |
| Rest of Asia-Pacific | 6.90% CAGR | Baseline infrastructure build-out |

China's provincial governments have committed over USD 45 Billion to hospital construction and renovation between 2023 and 2028, with infection control infrastructure accounting for an estimated 8–10% of total project costs [[4]](https://nhc.gov.cn). India's private hospital chains—Apollo, Fortis, and Max Healthcare—are standardizing infection prevention procurement across networks of 50+ facilities, driving bulk purchasing of automated sterilization and environmental monitoring systems and expanding the Infection Control Market in the subcontinent.

### South America

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Brazil | 58.20% of regional share | ANVISA sterilization standards |
| Argentina | 6.55% CAGR | Public-hospital modernization programs |
| Rest of South America | USD 1.65 Billion (2025) | NGO-funded infection prevention training |

Brazil's ANVISA has progressively tightened sterilization validation requirements for hospitals and ambulatory centers, creating a compliance-driven procurement cycle that anchors the Infection Control Market in South America [[15]](https://jointcommissioninternational.org). Argentina's federal government has directed provincial health ministries to upgrade central sterile supply departments in public hospitals, funded partly through Inter-American Development Bank loans.

### Middle East & Africa

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Saudi Arabia | 28.40% of regional share | Vision 2030 healthcare infrastructure |
| UAE | 7.20% CAGR | Medical tourism hub, JCI accreditation |
| South Africa | USD 1.05 Billion (2025) | National Health Insurance pilot |
| Egypt | 6.65% CAGR | Hospital capacity expansion |
| Rest of MEA | USD 1.42 Billion (2025) | Multilateral health-system investments |

Saudi Arabia's Vision 2030 healthcare pillar has earmarked over USD 65 Billion for hospital construction and health-system digitization, with infection prevention embedded as a core accreditation requirement for all new facilities [[17]](https://vision2030.gov.sa). The UAE's medical tourism strategy positions the country as a regional sterilization technology early adopter, supporting premium-segment growth in the Infection Control Market across the Gulf Cooperation Council.

## Competitive Benchmarking

## Competitive Benchmarking

The Infection Control Market exhibits medium concentration, with the top five players collectively holding an estimated 35–42% revenue share. The Herfindahl-Hirschman Index (HHI) falls in the 800–1,200 range, indicating a moderately fragmented competitive field where scale advantages in sterilization hardware coexist with a long tail of regional disinfectant and PPE manufacturers.

| Company | Est. Revenue Share Range | Key Offerings for Infection Control Market | Strategic Positioning |
| --- | --- | --- | --- |
| Steris plc | ~8–11% | Sterilizers, washer-disinfectors, contract sterilization services | Vertically integrated sterilization platform leader |
| 3M Company | ~6–9% | Biological indicators, sterilization wraps, skin antiseptics | Broad consumables portfolio with strong brand recall |
| Getinge AB | ~5–8% | Washer-disinfectors, sterilizers, surgical workflow solutions | Premium equipment focus on European and Asian markets |
| Ecolab Inc. | ~5–7% | Surface disinfectants, hand hygiene systems, water treatment | Chemical solutions integrated with facility services |
| Becton, Dickinson and Company | ~4–6% | Sharps disposal, infection prevention analytics, IV catheters | Device-plus-data combination strategy |
| Fortive Corporation (ASP) | ~3–5% | Low-temperature sterilizers, high-level disinfection systems | Specialist focus on advanced sterilization chemistries |
| Diversey Holdings | ~3–5% | Institutional cleaning chemicals, dosing systems | Facility hygiene partner for hospitals and long-term care |
| Belimed AG | ~2–4% | Washer-disinfectors, sterilizers for central sterile supply | Swiss-engineered premium sterilization hardware |
| Reckitt Benckiser Group | ~2–4% | Lysol and Dettol professional surface disinfectants | Consumer brand strength extending into institutional markets |
| Owens & Minor (Halyard) | ~2–3% | Surgical gowns, drapes, face masks, sterilization wraps | Protective barriers and procedural solutions specialist |

## Recent News & Developments

## Recent News & Developments

- Ecolab Inc. (2023 ): Acquired a cloud-based hand-hygiene compliance monitoring platform, adding AI-driven analytics to its infection prevention portfolio [[7]](https://journalofhospitalinfection.com).
- U.S. EPA (April 2024 ): Finalized revised National Emission Standards for EtO sterilization facilities, mandating up to 90% emission reductions and accelerating demand for alternative sterilization technologies [[3]](https://epa.gov).

- WHO (2021 ): Published the updated Global Patient Safety Action Plan 2024–2030, calling on all member states to designate national infection prevention budgets and report HAI data to a centralized registry [[2]](https://who.int).

## Report Scope

## Infection Control Market Report Scope

| Parameter | Details |
| --- | --- |
| Market Scope | Global Infection Control Market covering products, services, delivery modes, and end users |
| Study Period | 2021–2035 |
| CAGR | 6.90% (2026–2035) |
| Market Size (2025) | USD 109.50 Billion |
| Market Size (2035) | USD 213.38 Billion |
| Fastest Growing Segment | Ambulatory Surgery Centers (by end user); Protective Barriers (by product) |
| Companies Profiled | 10 (Steris, 3M, Getinge, Ecolab, BD, Fortive, Diversey, Belimed, Reckitt, Owens & Minor) |
| Valuation Currency | USD Billion |

## Frequently Asked Questions

**Q: How should hospital procurement teams evaluate total cost of ownership for low-temperature sterilizers?**
A: Factor in consumable cassette costs (USD 15–25 per cycle), annual maintenance contracts, and utility consumption alongside the USD 120,000–180,000 acquisition price [11]. Lifecycle cost over seven years often exceeds twice the purchase price.

**Q: What competitive moat distinguishes contract sterilization operators from in-house programs?**
A: Contract operators spread EPA-compliant infrastructure costs across 20–40 client facilities, achieving 30–40% lower per-cycle costs than single-site departments [9]. Scale-driven pricing and regulatory expertise create significant switching costs.

**Q: How does antimicrobial resistance (AMR) surveillance influence infection control procurement decisions?**
A: Facilities enrolled in the WHO GLASS reporting framework must maintain real-time antibiogram dashboards, which require integrated environmental monitoring and data analytics platforms [10]. AMR mandates are becoming a procurement trigger for bundled solutions.

**Q: What accreditation requirements drive infection control spending in emerging markets?**
A: JCI accreditation demands documented sterilization validation, hand-hygiene compliance monitoring, and environmental surveillance programs [15]. Private hospitals seeking international patient referrals treat these requirements as non-negotiable capital investments.

**Q: How are UV-C disinfection robots changing terminal cleaning economics?**
A: UV-C robots reduce terminal cleaning labor time by 30–40% and lower Clostridioides difficile surface contamination by over 50% in clinical trials [16]. ROI breakeven typically occurs within 14–18 months at high-turnover facilities.

**Q: What role do group purchasing organizations play in the Infection Control Market?**
A: GPOs aggregate demand across member hospitals to negotiate 15–25% discounts on sterilization consumables and disinfection chemicals [19]. They also standardize product formularies, simplifying vendor selection for smaller facilities.

**Q: How will the EU Corporate Sustainability Reporting Directive affect infection control supply chains?**
A: Manufacturers selling into EU hospitals will need to report Scope 3 emissions for disposable products and chemical disinfectants [14]. Vendors offering lifecycle-assessment-verified, lower-carbon product lines will gain a procurement advantage.

**Q: What is the current size of the infection control market?**
A: The infection control market reached USD 109.50 billion in 2025 and is projected to reach USD 213.38 billion by 2035.

**Q: What is the CAGR of the infection control market?**
A: The infection control market is projected to grow at a CAGR of 6.90% during the forecast period 2026–2035.

**Q: Which region leads the infection control market?**
A: North America holds the largest share at 36.20%, while Asia-Pacific is the fastest-growing region at 7.35% CAGR.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/infection-control-market-5901*